PSP
55 programs · 53 companies
Programs
55
Companies
53
Trials
49
MOAs
38
FXIaiBCMA ADCPI3KiWEE1iSHP2iPLK4iJAK1/2iPRMT5iSTINGagAHRant
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Phase 2 | WRN | ||
| AZN-3724 | Preclinical | PSMA | ||
| Rimatenlimab | Phase 2/3 | SGLT2 | ||
| Doxafotisoran | Phase 1 | Cl18.2 | ||
| VRT-1576 | Phase 2/3 | RET | ||
| Riluinavolisib | NDA/BLA | KIF18A | ||
| Sovarelsin | Phase 2 | CFTR | ||
| ASN-4879 | Phase 3 | CGRP | ||
| ASN-7408 | NDA/BLA | GPRC5D | ||
| Terazumab | Phase 2 | BTK | ||
| VYG-2926 | NDA/BLA | CD19 | ||
| 452-8741 | Phase 1 | CD19 | ||
| Semainavolisib | Phase 2/3 | SGLT2 | ||
| TEM-8322 | Preclinical | IL-23 | ||
| GUS-IIT-564 | Phase 3 | PD-1 | ||
| CRV-1020 | Approved | CDK4/6 | ||
| Olpavorutinib | Phase 2 | Tau | ||
| Adagranaritide | Phase 2 | CD20 | ||
| CYD-4746 | Phase 1 | PCSK9 | ||
| MRK-3812 | Phase 3 | CD3 | ||
| Ribomavacamten | Phase 3 | EZH2 | ||
| Nidazumab | Phase 1 | CD38 | ||
| CNT-6977 | Preclinical | SOS1 | ||
| DAS-6981 | Phase 2/3 | DLL3 | ||
| Pemivorutinib | NDA/BLA | MALT1 | ||
| CEL-9671 | NDA/BLA | CGRP | ||
| PCV-2362 | Phase 1 | TIGIT | ||
| Datorelsin | NDA/BLA | PRMT5 | ||
| SPA-7602 | Preclinical | BCMA | ||
| Mirifotisoran | Approved | BET | ||
| 456-4277 | Preclinical | KRASG12C | ||
| Voxafutibatinib | Phase 1/2 | GPRC5D | ||
| Nidainavolisib | Approved | Menin | ||
| PHM-5291 | Phase 3 | BCMA | ||
| Datomavacamten | Preclinical | CD19 | ||
| Doxazasiran | Phase 2/3 | PLK4 | ||
| 654-2851 | Preclinical | CD123 | ||
| Ivomavacamten | Phase 1/2 | AHR | ||
| Zenotuximab | Phase 2/3 | FGFR | ||
| CNT-5081 | Phase 3 | BET | ||
| SYN-6765 | Approved | PD-L1 | ||
| Terazanubrutinib | Phase 3 | KRASG12C | ||
| STA-4766 | Phase 1/2 | CD19 | ||
| Datoinavolisib | NDA/BLA | BCMA | ||
| Tezetenlimab | Phase 2 | PD-1 | ||
| Elraosocimab | Phase 3 | Cl18.2 | ||
| PRO-2782 | Preclinical | TYK2 | ||
| BIO-IIT-588 | Approved | GIP-R | ||
| APN-1617 | Phase 2 | PLK4 | ||
| PET-IIT-517 | Phase 2 | SMN2 | ||
| Gozefutibatinib | NDA/BLA | WRN | ||
| WST-4138 | Phase 1/2 | PD-1 | ||
| EGI-5078 | Phase 2 | FGFR | ||
| ANG-3408 | Phase 2/3 | BCL-2 | ||
| VIR-467 | Phase 3 | GPRC5D |
Trials (49)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03434604 | MRK-3745 | Phase 2 | Terminated |
| NCT03027128 | AZN-3724 | Preclinical | Recruiting |
| NCT04087308 | Doxafotisoran | Phase 1 | Terminated |
| NCT06074312 | VRT-1576 | Phase 2/3 | Completed |
| NCT03288970 | Sovarelsin | Phase 2 | Not yet recr... |
| NCT05835696 | ASN-4879 | Phase 3 | Recruiting |
| NCT03028230 | ASN-4879 | Phase 3 | Terminated |
| NCT06853067 | ASN-4879 | Phase 3 | Terminated |
| NCT04339086 | ASN-4879 | Phase 3 | Active |
| NCT08282023 | ASN-7408 | NDA/BLA | Completed |
| NCT06024357 | Terazumab | Phase 2 | Recruiting |
| NCT08525077 | VYG-2926 | NDA/BLA | Not yet recr... |
| NCT07660880 | 452-8741 | Phase 1 | Terminated |
| NCT06140559 | GUS-IIT-564 | Phase 3 | Recruiting |
| NCT07787002 | CRV-1020 | Approved | Terminated |
| NCT05033149 | Adagranaritide | Phase 2 | Completed |
| NCT08657490 | MRK-3812 | Phase 3 | Terminated |
| NCT05535908 | MRK-3812 | Phase 3 | Active |
| NCT07308482 | Ribomavacamten | Phase 3 | Recruiting |
| NCT03091800 | CNT-6977 | Preclinical | Recruiting |